SK bioscience narrows operating loss 42%, sets earnings recovery in motion

Pretax profit swings back into the black
IDT drives profitability improvements
Topline results for 21-valent pneumococcal vaccine expected next year
Global partnerships also expand in RSV prevention antibodies and more

SK bioscience is continuing its recovery, driven by improved profitability at its German subsidiary IDT Biologika (IDT) and increased sales of its own vaccines. Its pipeline, including a 21-valent pneumococcal vaccine being developed with Sanofi, is also emerging as a new pillar of medium- to long-term growth.

On November 12, SK bioscience announced that its consolidated revenue for the third quarter of 2026 rose 21% year over year to KRW 182.4 billion. Its operating loss narrowed 42% to KRW 11.2 billion, the lowest level in the past 11 quarters, while it swung to a pretax profit of KRW 6.1 billion. Improvements in the performance of its existing businesses have helped restore profitability even as the company continues to invest in research and development and production infrastructure.

A view of SK bioscience headquarters in Songdo, Yeonsu-gu, Incheon. SK bioscience

IDT and the company's own vaccines drive improved results

IDT is at the center of the improved performance. Since its acquisition by SK bioscience in 2024, IDT has increased both its revenue and profitability through greater production and operational efficiency and structural improvements. In the third quarter, IDT's revenue rose 21% year over year to KRW 113.1 billion, while its operating profit increased approximately 66% to KRW 9.6 billion. Operating profit for the first three quarters rose 56% to KRW 22.3 billion.

The company's own vaccines and licensed products also supported growth. Supplies of SkyVaricella, its chickenpox vaccine, to the Pan American Health Organization (PAHO) increased, and its Sanofi vaccine distribution business also grew. As its business base expands beyond its focus on the domestic market to overseas supplies and global product distribution, its business portfolio is becoming more diversified.

Phase 3 results for 21-valent pneumococcal vaccine expected in second half of 2027

A key part of the company's medium- to long-term growth strategy is GBP410, a 21-valent pneumococcal conjugate vaccine being jointly developed with Sanofi. GBP410 is a next-generation vaccine candidate designed to protect against a broader range of infections by targeting 21 pneumococcal serotypes. A global Phase 3 clinical trial is underway, targeting major markets including South Korea, the United States and Europe.

Topline results from the global Phase 3 trial are expected in the second half of 2027. The collaboration with Sanofi links global clinical development with commercialization capabilities, signaling the company's ambition to expand its business model beyond its existing vaccine production and supply operations into next-generation vaccine development.

Investment in commercialization is also continuing. SK bioscience has completed the expansion of commercial production facilities at its L HOUSE vaccine plant in Andong, North Gyeongsang Province, strengthening its capacity to supply global markets. Long-term funding of KRW 300 billion secured through the National Growth Fund is expected to be used for research and development, commercialization preparations and upgrades to production facilities.

Expanding global partnerships in RSV prevention antibodies, Ebola vaccines and more

Development is also progressing on next-generation pipeline candidates targeting emerging infectious diseases. RSM01, a respiratory syncytial virus (RSV) prevention antibody candidate licensed from the Gates Medical Research Institute (Gates MRI), a research institution under the Gates Foundation, is being advanced for global pediatric clinical development. After receiving research funding from the RIGHT Foundation, the company submitted an application in South Africa to conduct a global pediatric Phase 1b clinical trial.

In addition, SK bioscience and IDT are participating in Merck's (MSD) next-generation Ebola vaccine program and the European Health and Digital Executive Agency's (HaDEA) next-generation influenza vaccine project. Last month, they also joined a project to develop and produce a Bundibugyo Ebola vaccine, supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA), together with the International AIDS Vaccine Initiative (IAVI) and others.

Industry observers say SK bioscience's medium- to long-term strategy is taking shape around three pillars: improving the profitability of its existing businesses, expanding its global contract development and manufacturing organization (CDMO) business, and developing next-generation vaccine pipelines. Analysts say that if IDT's contribution to earnings grows and clinical results for key pipeline candidates such as GBP410 become clearer, the company's current recovery could lead to a stronger foundation for growth.

An SK bioscience spokesperson said, "We will continue to improve profitability based on our existing vaccine business and IDT's global production capabilities, while focusing on turning development progress in our clinical-stage pipeline into future businesses." The spokesperson added, "We will expand vaccine development and production projects through global partnerships and secure medium- to long-term growth drivers by commercializing next-generation vaccines."

This content was produced with the assistance of AI translation services.